|
|
|
| home > ebr > Autumn 2004 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR. |
 |
| |
|
|
| In her Editor's Letter, Dr Helen Tayton-Martin takes a look at the topics in this issue |
|
|
|
|
| Dr Majid Mehtali, Vice President of Research & Development at Vivalis SA, underlines the potential of Embryonic Stem Cells: Current and Future Industrial Applications |
|
|
| Unravelling the Mysteries of Alzheimer's - the search for a cure continues, by G Steven Burrill, CEO of Burrill & Company |
|
|
| Sunil Saini, Director of Biomaterials at Therics, maps the development of a new domain in A Perspective in Orthopaedic Tissue Engineering |
|
|
| Hans Herklots, Media and Investor Relations Director at IsoTis OrthoBiologics, looks at the potential transformation of orthopaedics, in Biologics are Entering the Orthopaedic Arena |
|
|
|
| How are ideas transformed into a thriving business? Nigel Wild, Managing Director of Oxfordshire BioTechNet Ltd, discusses the options in Funding and Mentoring - The Keys to the Biotech Kingdom |
|
|
| In Technology Transfer from Universities, Tom Hockaday, Executive Director of Isis Innovations Ltd, welcomes the continuing interest in collaboration between academia and the business community |
|
|
| Incubators must form an integral part of our infrastructure for supporting young companies, asserts Toni Wanklin, Development Manager at UK Business Incubation, in Breaking Through The Barrier: How Bio-Incubators Support Tomorrow's World-Class Entrepreneurs |
|
|
| Fiona Brown, Public Relations Consultant, considers today's funding environment and the particular hurdles inherent in biotechnology in Uniting Science and Business: The Challenges for Biotech Start-ups |
|
|
| Science, finance and IPR: conditions for Finnish entrepreneurs uncovered in Challenges for Biotech Start-Ups: A Nordic Perspective, by Professor Kalevi Kairemo, Medical Director and Dr Oula Pe-ate Medina, CEO of CTT Cancer Targeting Technologies |
|
|
| Continuing from Part 1 in our summer issue, Beyond Financial Analysis - Scientific Due Diligence in Pharma and Biotech: Part 2 focuseson clinical trials. By Dr Konrad Burk, Founder of ClinDescience GmbH, William McCulloch, CMO of Gloucester Pharmaceuticals, Dr Alexander von Nieciecki, CEO of BioProof, and Dr Wolfgang Meyer, Senior Director of European Drug Regulatory Affairs and Dr Benno Rattel, Senior Director of Drug Development at GPC Biotech AG |
|
|
|
| Valuing Innovation: Patient Access to Novel Therapies, by Alastair Kent, Director of the Genetic Interest Group, explores the disjunction between scientific advances and practical resources |
|
|
| Dr Sarah Rawlings, Policy and Information Officer at Breakthrough Breast Cancer, examines the 'postcode lottery' of UK health care in NICE Implementation - The Patient Perspective |
|
|
|
| Dr Stephen Hammond, CEO of Scottish Biomedical, investigates the factors to be weighed in the Successful Outsourcing of Preclinical Drug Discovery |
|
|
| In Electronic Diary Solutions: Enhanced Collection of Patient Reported Outcomes Data, Dr Bill Byrom, Product Development Director at ClinPhone Group Ltd, details alternatives to the traditional paper-based diary that can reduce the likelihood of distorted results |
|
|
| Ivan N Rich, Founder, Chairman and CEO of HemoGenix, Inc, discusses Stem Cell Haemotoxicity Testing to Predict Toxic Side-Effects and as a Tool for Safety Monitoring during Drug Development |
|
|
| Dr Wendy M Shaw, Associate Director (Europe) of the Late Phase Group at Kendle International Inc, explains the function of post-marketing surveillance in recording and studying new adverse drug reactions in Opportunities and Challenges of Pan European Post-Marketing Surveillance Programmes |
|
|
|
| Identifying Appropriate RNA Interference Drug Candidates opens the door to a whole new class of treatments - by Dr David A Bumcrot, Director, Preclinical at Alnylam Pharmaceuticals, Inc |
|
|
| Angelika Bonin-Debs, Director of Business Development and Strategic Alliances at Xantos Bioscience, charts the advent of RNAi and its role in Loss-of-Function and Gain-of-Function - Two Complementing Genome-Wide Technologies For Drug Discovery and Target Validation |
|
|
| Automation and Robotics in High Throughput Protein Crystallography explained by Bernhard Rupp, Macromolecular Crystallography and Structural Genomics Group of the Lawrence Livermore National Laboratory, University of California |
|
|
| Methods of column protection are presented in Syringe Filter Efficiency and the Effect of Filtration on HPLC Column Life, by Dr Weibing Ding, Senior Staff Scientist and Larry Scheer, Business Development Manager at Pall Corporation |
|
|
|
| Regu Chandar Gnanapragasam, Assistant Manager of the Industrial & Trade Division of the Penang Development Corporation, Simon Saxby, Chief Executive Officer at Alpha Biologics Sdn Bhd and Dr Malcolm Blackwell, Chief Executive Officer at Progenix Research Sdn Bhd, unveil a new development zone for biotech in Malaysian Biotechnology Initiative for the State of Penang |
|
|
|
| Innovation, investment and government support - Nicola Watkinson, Senior Investment Commissioner, Europe, at Invest Australia, sets the scene in Australian Biotechnology - An Untapped Opportunity |
|
|
|
| CMP Information anticipate this year's BioTech Hot Spot, a unique networking facility at CPhI Worldwide/ICSE |
|
|
| Answering the growing need for partnership opportunities, BIO-Europe 2004: Europe's Largest Partnering Conference, Provides a Platform for Deal-Making and Investors |
|
|
| Tracing global industry trends in Resurgent, Refocused and On the Threshold - Insights from Ernst & Young's 11th Annual Global Biotechnology Report, by EBR Editor Helen Tayton-Martin |
|
|
| Advokat Lars Rambe, Head of Life Science at Adokatfirman Delphi & Co, compares IP systems in the EU and US in Commercialisation of Inventions from Scandinavian Universities - A Challenge and an Opportunity |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Signant Health Senior Vice President Dr. David Daniel Honored in PharmaVOICE 100
Philadelphia, PA – August 1, 2019: Signant Health (formerly CRF Health
and Bracket) today announces that its Senior Vice President, Dr. David
Daniel, has been selected by PharmaVOICE as one of the top 100 most
inspiring people within the life sciences sector. Dr. Daniel was
selected from a large cross section of established professionals in the
life sciences industry for his passion to continually improve the way in
which science, technology and service interact. This honor swiftly
follows another recent mark of distinction for Dr. Daniel, having been
co-awarded the 2019 ISCDD Scientific Leadership Award.
More info >> |
|
 |
White Papers |
 |
|
Mauritius Island – An Emerging Centre for R&D in Biotechnology and the Life Sciences
CIDP (Centre International de Développement Pharmaceutique)
Mauritius, the tropical island situated in the Indian Ocean and known
worldwide for its beautiful beaches, is also internationally recognised
for its rule of law, and political and social stability. Over the past
few years, the economy has been successfully transitioned from a
monocrop to a diversified innovation-driven and knowledge-based economy,
resting on agribusiness, export-oriented manufacturing, tourism,
financial services, property development and real estate, ICT-BPO, the
seafood industry, a free port, logistics and a nascent ocean economy.
Emerging sectors such as healthcare and life sciences are presenting
some niche areas for the taking, and the enabling environment is being
put in place to make it happen - especially in the light of sustained
growth within pharmaceutical, medical device, and clinical research.
Important
international players are already in operation locally as the country
has established the appropriate legal and regulatory frameworks based on
international norms, for the development of a strong biomedical
research sector.
More info >> |
|
 |
Industry Events |
 |
World Vaccine Congress Europe
28-31 October 2019, Barcelona, Spain
The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona.
It’s the biggest and most established European vaccine event with over 250 speakers,
700+ senior vaccine attendees, hundreds of networking hours.
It cover key topics across the complete vaccine value chain bringing together:
• Government
• big pharma
• big biotech
• SME Biotech
• academia
and the wider service provider community and their partners to discuss scientific,
clinical and strategic advances and opportunities.
The event has already confirmed over 200 speakers from Human Vaccine Project, OECD,
CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more…
There is a Super Early Bird offer available – Find Out More
www.terrapinn.com/WVCEU/EBR
More info >> |
|
|
